Premium
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
Author(s) -
Brennan Xavier,
Withers Barbara,
Jabbour Andrew,
Milliken Sam,
Kotlyar Eugene,
Fay Keith,
Ma David,
Muthiah Kavitha,
Hamad Nada,
Dodds Anthony,
Bart Nikki,
Keogh Anne,
Hayward Chris,
Macdonald Peter,
Moore John
Publication year - 2022
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.15926
Subject(s) - medicine , dexamethasone , bortezomib , cyclophosphamide , melphalan , al amyloidosis , amyloidosis , cardiac amyloidosis , oncology , chemotherapy , multiple myeloma , immunoglobulin light chain , immunology , antibody
Abstract Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.